Skip to main content Skip to main navigation menu Skip to site footer
  • \
    Start Submission Become a Reviewer

    The role of ALDH2 and its substrates in central nervous system disorders

    • Yashuang Chen
    • Fengyuan Tian
    • Shu Meng
    • Jiayu Wang


    Abstract

    Background: Aldehyde Dehydrogenase 2 (ALDH2) is a mitochondrial dehydrogenase enzyme primarily tasked with the detoxification of acetaldehyde produced from alcohol metabolism and endogenous aldehydes. These aldehyde compounds, such as 4-Hydroxynonenal (4-HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL), are predominantly generated through lipid peroxidation and are known to form adducts with proteins, DNA, and lipids, thereby inducing neurotoxicity.

    Methods: This review examines the role of ALDH2 in central nervous system (CNS) diseases by analyzing epidemiological studies and disease models. The focus is on understanding the impact of the ALDH2 rs671 G>A polymorphism, which reduces or eliminates enzyme activity.

    Results: This genetic polymorphism of ALDH2 is closely associated with the onset of various central nervous system (CNS) diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, and stroke potentially linked to the accumulation of aldehyde compounds within the CNS.

    Conclusions: A deeper understanding of the mechanisms by which ALDH2 influences these diseases will enhance therapeutic strategies for patients carrying the ALDH2 rs671 polymorphism and also offer new insights for the prevention and diagnosis of these conditions.

    Keywords: ALDH2 Alzheimer’s disease Parkinson’s disease Schizophrenia Stroke 4-HNE
    Section

    References

    1. Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends in neurosciences. 2013;36(10):587-97.
    2. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148(6):1145-59.
    3. Rios L, Pokhrel S, Li SJ, Heo G, Haileselassie B, Mochly-Rosen D. Targeting an allosteric site in dynamin-related protein 1 to inhibit Fis1-mediated mitochondrial dysfunction. Nature communications. 2023;14(1):4356.
    4. Kumar S, Chhabra V, Shenoy S, Daksh R, Ravichandiran V, Swamy R, Kumar N. Role of Flavonoids in Modulation of Mitochondria Dynamics during Oxidative Stress. Mini reviews in medicinal chemistry. 2023.
    5. Borbolis F, Mytilinaiou E, Palikaras K. The Crosstalk between Microbiome and Mitochondrial Homeostasis in Neurodegeneration. Cells. 2023;12(3).
    6. Schneider C, Porter NA, Brash AR. Routes to 4-hydroxynonenal: fundamental issues in the mechanisms of lipid peroxidation. The Journal of biological chemistry. 2008;283(23):15539-43.
    7. Lachenmeier DW, Kanteres F, Rehm J. Carcinogenicity of acetaldehyde in alcoholic beverages: risk assessment outside ethanol metabolism. Addiction (Abingdon, England). 2009;104(4):533-50.
    8. Di Domenico F, Tramutola A, Butterfield DA. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free radical biology & medicine. 2017;111:253-61.
    9. Milkovic L, Zarkovic N, Marusic Z, Zarkovic K, Jaganjac M. The 4-Hydroxynonenal-Protein Adducts and Their Biological Relevance: Are Some Proteins Preferred Targets? Antioxidants (Basel, Switzerland). 2023;12(4).
    10. Im PK, Wright N, Yang L, Chan KH, Chen Y, Guo Y, et al. Alcohol consumption and risks of more than 200 diseases in Chinese men. Nature medicine. 2023;29(6):1476-86.
    11. Deng L, Ding L, Duan X, Peng Y. Shared molecular signatures between coronavirus infection and neurodegenerative diseases provide targets for broad-spectrum drug development. Scientific reports. 2023;13(1):5457.
    12. Cronin-Furman EN, Borland MK, Bergquist KE, Bennett JP, Jr., Trimmer PA. Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. Mol Neurodegener. 2013;8:6.
    13. Murphy TC, Amarnath V, Gibson KM, Picklo MJ, Sr. Oxidation of 4-hydroxy-2-nonenal by succinic semialdehyde dehydrogenase (ALDH5A). Journal of neurochemistry. 2003;86(2):298-305.
    14. Seike T, Chen CH, Mochly-Rosen D. Impact of common ALDH2 inactivating mutation and alcohol consumption on Alzheimer's disease. Front Aging Neurosci. 2023;15:1223977.
    15. Raghunathan L, Hsu LC, Klisak I, Sparkes RS, Yoshida A, Mohandas T. Regional localization of the human genes for aldehyde dehydrogenase-1 and aldehyde dehydrogenase-2. Genomics. 1988;2(3):267-9.
    16. Braun T, Bober E, Singh S, Agarwal DP, Goedde HW. Evidence for a signal peptide at the amino-terminal end of human mitochondrial aldehyde dehydrogenase. FEBS letters. 1987;215(2):233-6.
    17. Yoshida A, Huang IY, Ikawa M. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci U S A. 1984;81(1):258-61.
    18. Gao J, Hao Y, Piao X, Gu X. Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention. International journal of molecular sciences. 2022;23(5).
    19. Serio RN, Lu C, Gross SS, Gudas LJ. Different Effects of Knockouts in ALDH2 and ACSS2 on Embryonic Stem Cell Differentiation. Alcoholism, clinical and experimental research. 2019;43(9):1859-71.
    20. Shi L, Tu BP. Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Current opinion in cell biology. 2015;33:125-31.
    21. Zhong H, Yin H. Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: focusing on mitochondria. Redox biology. 2015;4:193-9.
    22. Zambelli VO, Gross ER, Chen CH, Gutierrez VP, Cury Y, Mochly-Rosen D. Aldehyde dehydrogenase-2 regulates nociception in rodent models of acute inflammatory pain. Science translational medicine. 2014;6(251):251ra118.
    23. Haigis MC, Yankner BA. The aging stress response. Molecular cell. 2010;40(2):333-44.
    24. 2022 Alzheimer's disease facts and figures. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022;18(4):700-89.
    25. Yi L, Luo M, Wang M, Dong Z, Du Y. Fangchinoline alleviates cognitive impairments through enhancing autophagy and mitigating oxidative stress in Alzheimer's disease models. Frontiers in cell and developmental biology. 2023;11:1288506.
    26. Aquilani R, Cotta Ramusino M, Maestri R, Iadarola P, Boselli M, Perini G, et al. Several dementia subtypes and mild cognitive impairment share brain reduction of neurotransmitter precursor amino acids, impaired energy metabolism, and lipid hyperoxidation. Front Aging Neurosci. 2023;15:1237469.
    27. Shin IS, Stewart R, Kim JM, Kim SW, Yang SJ, Shin HY, et al. Mitochondrial aldehyde dehydrogenase polymorphism is not associated with incidence of Alzheimer's disease. International journal of geriatric psychiatry. 2005;20(11):1075-80.
    28. Kim JM, Stewart R, Shin IS, Jung JS, Yoon JS. Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer's disease in an older Korean population. Neurobiology of aging. 2004;25(3):295-301.
    29. Zhou S, Huriletemuer, Wang J, Zhang C, Zhao S, Wang de S, et al. Absence of association on aldehyde dehydrogenase 2 (ALDH2) polymorphism with Mongolian Alzheimer patients. Neuroscience letters. 2010;468(3):312-5.
    30. Ohta S, Ohsawa I, Kamino K, Ando F, Shimokata H. Mitochondrial ALDH2 deficiency as an oxidative stress. Annals of the New York Academy of Sciences. 2004;1011:36-44.
    31. Ueno M, Yoshino Y, Mori H, Funahashi Y, Kumon H, Ochi S, et al. Association Study and Meta-Analysis of Polymorphisms and Blood mRNA Expression of the ALDH2 Gene in Patients with Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2022;87(2):863-71.
    32. Komatsu M, Shibata N, Ohnuma T, Kuerban B, Tomson K, Toda A, et al. Polymorphisms in the aldehyde dehydrogenase 2 and dopamine β hydroxylase genes are not associated with Alzheimer's disease. Journal of neural transmission (Vienna, Austria : 1996). 2014;121(4):427-32.
    33. Jin X, Long T, Chen H, Zeng Y, Zhang X, Yan L, Wu C. Associations of Alcohol Dehydrogenase and Aldehyde Dehydrogenase Polymorphism With Cognitive Impairment Among the Oldest-Old in China. Front Aging Neurosci. 2021;13:710966.
    34. Ma L, Lu ZN. Role of ADH1B rs1229984 and ALDH2 rs671 gene polymorphisms in the development of Alzheimer's disease. Genetics and molecular research : GMR. 2016;15(4).
    35. Wang B, Wang J, Zhou S, Tan S, He X, Yang Z, et al. The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. Journal of the neurological sciences. 2008;268(1-2):172-5.
    36. Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, et al. Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochemical and biophysical research communications. 2000;273(1):192-6.
    37. Wu YY, Lee YS, Liu YL, Hsu WC, Ho WM, Huang YH, et al. Association Study of Alcohol Dehydrogenase and Aldehyde Dehydrogenase Polymorphism With Alzheimer Disease in the Taiwanese Population. Frontiers in neuroscience. 2021;15:625885.
    38. Ohsawa I, Kamino K, Nagasaka K, Ando F, Niino N, Shimokata H, Ohta S. Genetic deficiency of a mitochondrial aldehyde dehydrogenase increases serum lipid peroxides in community-dwelling females. Journal of human genetics. 2003;48(8):404-9.
    39. Bai J, Mei Y. Overexpression of aldehyde dehydrogenase-2 attenuates neurotoxicity induced by 4-hydroxynonenal in cultured primary hippocampal neurons. Neurotoxicity research. 2011;19(3):412-22.
    40. Kanamaru T, Kamimura N, Yokota T, Iuchi K, Nishimaki K, Takami S, et al. Oxidative stress accelerates amyloid deposition and memory impairment in a double-transgenic mouse model of Alzheimer's disease. Neuroscience letters. 2015;587:126-31.
    41. Nakashima Y, Ohsawa I, Konishi F, Hasegawa T, Kumamoto S, Suzuki Y, Ohta S. Preventive effects of Chlorella on cognitive decline in age-dependent dementia model mice. Neuroscience letters. 2009;464(3):193-8.
    42. D'Souza Y, Elharram A, Soon-Shiong R, Andrew RD, Bennett BM. Characterization of Aldh2 (-/-) mice as an age-related model of cognitive impairment and Alzheimer's disease. Molecular brain. 2015;8:27.
    43. Ohta S, Ohsawa I. Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. Journal of Alzheimer's disease : JAD. 2006;9(2):155-66.
    44. Mehder RH, Bennett BM, Andrew RD. Age-Related Neuronal Deterioration Specifically Within the Dorsal CA1 Region of the Hippocampus in a Mouse Model of Late Onset Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2021;79(4):1547-61.
    45. Ghoweri AO, Gagolewicz P, Frazier HN, Gant JC, Andrew RD, Bennett BM, Thibault O. Neuronal Calcium Imaging, Excitability, and Plasticity Changes in the Aldh2-/- Mouse Model of Sporadic Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2020;77(4):1623-37.
    46. Luo J, Lee SH, VandeVrede L, Qin Z, Ben Aissa M, Larson J, et al. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease. Mol Neurodegener. 2016;11:35.
    47. Elharram A, Czegledy NM, Golod M, Milne GL, Pollock E, Bennett BM, Shchepinov MS. Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer's disease. The FEBS journal. 2017;284(23):4083-95.
    48. Yang Y, Chen W, Wang X, Ge W. Impact of mitochondrial aldehyde dehydrogenase 2 on cognitive impairment in the AD model mouse. Acta biochimica et biophysica Sinica. 2021;53(7):837-47.
    49. Dawson TM, Dawson VL. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nature neuroscience. 2002;5 Suppl:1058-61.
    50. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6.
    51. Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson's disease: current progress and future prospects. Acta neurologica Scandinavica. 2016;134(5):314-26.
    52. Pradhan SP, Tejaswani P, Behera A, Sahu PK. Phytomolecules from conventional to nano form: Next-generation approach for Parkinson's disease. Ageing research reviews. 2023;93:102136.
    53. Zhang X, Ye YL, Wang YN, Liu FF, Liu XX, Hu BL, et al. Aldehyde dehydrogenase 2 genetic variations may increase susceptibility to Parkinson's disease in Han Chinese population. Neurobiology of aging. 2015;36(9):2660.e9-13.
    54. Chen J, Huang W, Cheng CH, Zhou L, Jiang GB, Hu YY. Association Between Aldehyde dehydrogenase-2 Polymorphisms and Risk of Alzheimer's Disease and Parkinson's Disease: A Meta-Analysis Based on 5,315 Individuals. Frontiers in neurology. 2019;10:290.
    55. Lin CY, Yu RL, Wu RM, Tan CH. Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease. Scientific reports. 2019;9(1):18950.
    56. Yu RL, Tu SC, Wu RM, Lu PA, Tan CH. Interactions of COMT and ALDH2 Genetic Polymorphisms on Symptoms of Parkinson's Disease. Brain sciences. 2021;11(3).
    57. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature: New biology. 1973;245(144):150-1.
    58. Chen AH, Zhang P, Yin WL, Wang L, Zou W, Tang XQ. Role of aldehyde dehydrogenase 2 in 1-methy-4-phenylpyridinium ion-induced aldehyde stress and cytotoxicity in PC12 cells. Neurochemical research. 2014;39(9):1767-75.
    59. Wang Y, Zhang X. The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia. Psychiatry research. 2023;332:115708.
    60. Bošković M, Vovk T, Kores Plesničar B, Grabnar I. Oxidative stress in schizophrenia. Current neuropharmacology. 2011;9(2):301-12.
    61. Emiliani FE, Sedlak TW, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Current opinion in psychiatry. 2014;27(3):185-90.
    62. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxidants & redox signaling. 2011;15(7):2011-35.
    63. Wang JF, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar disorders. 2009;11(5):523-9.
    64. Zheng F, Yan H, Liu B, Yue W, Fan L, Liao J, et al. ALDH2 Glu504Lys Confers Susceptibility to Schizophrenia and Impacts Hippocampal-Prefrontal Functional Connectivity. Cerebral cortex (New York, NY : 1991). 2017;27(3):2034-40.
    65. Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, et al. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan. Journal of psychiatric research. 2015;69:50-6.
    66. Gu X, Dou M, Yuan M, Zhang W. Identifying novel proteins underlying loneliness by integrating GWAS summary data with human brain proteomes. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023;48(7):1087-97.
    67. Ramos-Loyo J, Medina-Hernández V, Estarrón-Espinosa M, Canales-Aguirre A, Gómez-Pinedo U, Cerdán-Sánchez LF. Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2013;44:154-61.
    68. Cook RL, Parker HM, Donges CE, O'Dwyer NJ, Cheng HL, Steinbeck KS, et al. Omega-3 polyunsaturated fatty acids status and cognitive function in young women. Lipids in health and disease. 2019;18(1):194.
    69. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003;28 Suppl 2:1-16.
    70. The burden of diseases and risk factors in Bangladesh, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Global health. 2023;11(12):e1931-e42.
    71. Marsh JD, Keyrouz SG. Stroke prevention and treatment. Journal of the American College of Cardiology. 2010;56(9):683-91.
    72. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. The Lancet Neurology. 2007;6(12):1106-14.
    73. Falcone GJ, Malik R, Dichgans M, Rosand J. Current concepts and clinical applications of stroke genetics. The Lancet Neurology. 2014;13(4):405-18.
    74. Kilarski LL, Achterberg S, Devan WJ, Traylor M, Malik R, Lindgren A, et al. Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology. 2014;83(8):678-85.
    75. Cho Y, Lin K, Lee SH, Yu C, Valle DS, Avery D, et al. Genetic influences on alcohol flushing in East Asian populations. BMC genomics. 2023;24(1):638.
    76. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet (London, England). 2019;393(10183):1831-42.
    77. Millwood IY, Im PK, Bennett D, Hariri P, Yang L, Du H, et al. Alcohol intake and cause-specific mortality: conventional and genetic evidence in a prospective cohort study of 512 000 adults in China. The Lancet Public health. 2023;8(12):e956-e67.
    78. Xu YL, Hu YY, Li JW, Zhou L, Li L, Niu YM. Aldehyde dehydrogenase 2 rs671G>A polymorphism and ischemic stroke risk in Chinese population: a meta-analysis. Neuropsychiatric disease and treatment. 2019;15:1015-29.
    79. Jiang Y, He J, Liu H, Xu Z. Association between ALDH2 rs671 polymorphism and risk of ischemic stroke: A protocol for systematic review and meta analysis. Medicine. 2020;99(21):e20206.
    80. Shi M, Kelly TN, Zhu Z, Li C, Shen C, Sun Y, et al. Large-Scale Targeted Sequencing Study of Ischemic Stroke in the Han Chinese Population. Journal of the American Heart Association. 2022;11(19):e025245.
    81. Zhang S, Luo W, Pan T, Xie J, Xu Z, Fang Y. ALDH2 rs671 Polymorphism Likely a Risk Factor for Hemorrhagic Stroke: A Hospital-Based Study. International journal of general medicine. 2023;16:1471-8.
    82. Geltser BI, Kurpatov IG, Kotelnikov VN, Zayats YV. Chronic obstructive pulmonary disease and cerebrovascular diseases: functional and clinical aspect of comorbidity. Terapevticheskii arkhiv. 2018;90(3):81-8.
    83. Sun A, Ren J. ALDH2, a novel protector against stroke? Cell Res. 2013;23(7):874-5.
    84. Zhang R, Liu B, Fan X, Wang W, Xu T, Wei S, et al. Aldehyde Dehydrogenase 2 Protects Against Post-Cardiac Arrest Myocardial Dysfunction Through a Novel Mechanism of Suppressing Mitochondrial Reactive Oxygen Species Production. Frontiers in pharmacology. 2020;11:373.
    85. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9.
    86. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nature genetics. 2011;43(6):531-8.
    87. Guo JM, Liu AJ, Zang P, Dong WZ, Ying L, Wang W, et al. ALDH2 protects against stroke by clearing 4-HNE. Cell Res. 2013;23(7):915-30.
    88. Xia P, Zhang F, Yuan Y, Chen C, Huang Y, Li L, et al. ALDH 2 conferred neuroprotection on cerebral ischemic injury by alleviating mitochondria-related apoptosis through JNK/caspase-3 signing pathway. International Journal of Biological Sciences. 2020;16(8):1303-23.
    89. Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer's disease in an older Korean population. Neurobiology of aging. 2004;25(3):295-301.
    90. Michel TM, Käsbauer L, Gsell W, Jecel J, Sheldrick AJ, Cortese M, et al. Aldehyde dehydrogenase 2 in sporadic Parkinson's disease. Parkinsonism & related disorders. 2014;20 Suppl 1:S68-72.
    91. Zhao CC, Cai HB, Wang H, Pan SY. Role of ADH2 and ALDH2 gene polymorphisms in the development of Parkinson's disease in a Chinese population. Genetics and molecular research : GMR. 2016;15(3).

    How to Cite

    “The Role of ALDH2 and Its Substrates in Central Nervous System Disorders”. Human Brain, vol. 3, no. 2, July 2024, https://doi.org/10.37819/hb.2.1812.
    ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
    Download Citation
    Endnote/Zotero/Mendeley (RIS) BibTeX

    How to Cite

    “The Role of ALDH2 and Its Substrates in Central Nervous System Disorders”. Human Brain, vol. 3, no. 2, July 2024, https://doi.org/10.37819/hb.2.1812.

    HTML
    90

    Total
    80

    Share

    Search Panel

    Yashuang Chen
    Google Scholar
    Pubmed
    JDMFS Journal

    Fengyuan Tian
    Google Scholar
    Pubmed
    JDMFS Journal

    Shu Meng
    Google Scholar
    Pubmed
    JDMFS Journal

    Jiayu Wang
    Google Scholar
    Pubmed
    JDMFS Journal

    Downloads

    Article Details

    Most Read This Month

    License

    Copyright (c) 2024 Yashuang Chen , Fengyuan Tian, Shu Meng, Jiayu Wang

    Creative Commons License

    This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

    Copyright © 2023 EurAsia Academic Publishing Group. All rights reserved